Clinical Trials in Edmonton, AB
View medical research that is recruiting in Edmonton, AB. Filter by phase, distance, and inclusion criteria to find cutting edge treatments & access premium care.
Condition
Location
Distance
10 miles
50 miles
Any
Age
Search
Clinical Trials
Clinical Trials in Edmonton, AB
2
Effectiveness
3
Safety
Nivolumab-relatlimab FDC
for Colorectal Cancer
Edmonton, Canada
18+
All Sexes
Phase 3
Recruiting
Metastatic
Edmonton, Canada
18+
All Sexes
The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of late-line microsatellite stable (MSS) metastatic colorectal cancer (mCRC) participants who failed at least 1 but no more than 4 prior lines of therapy for metastatic disease.
1
Effectiveness
2
Safety
Pembrolizumab
for Lymphoma
Edmonton, Canada
18+
All Sexes
Phase 2
Recruiting
Stage I
Edmonton, Canada
18+
All Sexes
This study is evaluating whether a new drug called pembrolizumab can be used to treat cancer.
3
Effectiveness
3
Safety
PAH Therapies
for Pulmonary Arterial Hypertension
Edmonton, Canada
18+
All Sexes
Phase 4
Recruiting
Edmonton, Canada
18+
All Sexes
This study is evaluating whether there are differences in the time to death due to pulmonary arterial hypertension (PAH) or first hospitalization due to PAH in people with idiopathic pulmonary fibrosis (IPF) and people with other forms
1
Effectiveness
2
Safety
CC-93538
for Eczema, Infantile
Oakville, Canada
18+
All Sexes
Phase 2
Waitlist Available
Oakville, Canada
18+
All Sexes
This study is evaluating whether a drug may help treat atopic dermatitis.
2
Effectiveness
3
Safety
Vedolizumab IV
for Ileocolitis
Edmonton, Canada
< 18
All Sexes
Phase 3
Recruiting
Edmonton, Canada
< 18
All Sexes
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no signs of inflammation. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive either a high dose or low dose of vedolizumab once every 8 weeks. They will receive the same dose every time.
1
Effectiveness
2
Safety
MEDI3506
for Asthma
Edmonton, Canada
18+
All Sexes
Phase 2
Recruiting
Edmonton, Canada
18+
All Sexes
Study D9181C00001 is a Phase II, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of MEDI3506 in adult participants with uncontrolled moderate to severe asthma on standard of care (SOC). Up to approximately 80 sites globally will participate in this study. Approximately 228 participants will be randomized to 3 treatment groups in a 1:1:1 ratio to receive MEDI3506 dose 1, MEDI3506 dose 2, or placebo.
2
Effectiveness
3
Safety
Capivasertib
for Hypersensitivity
La Jolla, CA
18+
Male
Phase 3
Recruiting
Metastatic
La Jolla, CA
18+
Male
This study is evaluating whether a combination of two drugs may help treat prostate cancer.
2
Effectiveness
3
Safety
Darolutamide (Nubeqa, BAY1841788)
for Malignancies
Camp Hill, PA
18+
Male
Phase 3
Recruiting
Camp Hill, PA
18+
Male
This study is evaluating whether the continuation of a drug which was previously shown to be effective in treating prostate cancer may be effective in treating prostate cancer.
2
Effectiveness
3
Safety
Cabozantinib
for Prostate Cancer
Houston, TX
18+
Male
Phase 3
Recruiting
Grade I
Houston, TX
18+
Male
This study is evaluating whether a drug may help treat prostate cancer.
1
Effectiveness
1
Safety
BMS-986315
for Cancer
Edmonton, Canada
18+
All Sexes
Phase 1 & 2
Recruiting
Locally Advanced
Edmonton, Canada
18+
All Sexes
This study is evaluating whether a drug may help treat solid tumors.
1
Effectiveness
2
Safety
Raltegravir
for Cholangitis
Edmonton, Canada
18+
All Sexes
Phase 2
Recruiting
Edmonton, Canada
18+
All Sexes
This study is evaluating whether a drug combination can improve liver function in people with primary biliary cholangitis.
2
Effectiveness
3
Safety
RBX2660
for Clostridium Infections
Decatur, GA
18+
All Sexes
Phase 3
Recruiting
1 Prior Treatment
Decatur, GA
18+
All Sexes
This study is evaluating whether a suspension of intestinal microbes may help treat recurrent Clostridium difficile infection.
2
Effectiveness
3
Safety
Mirikizumab
for Ileocolitis
Seattle, WA
Any Age
All Sexes
Phase 3
Recruiting
Seattle, WA
Any Age
All Sexes
This study is evaluating whether a drug may help treat Crohn's disease.
1
Effectiveness
2
Safety
Hydromorphone
for Wounds
Edmonton, Canada
< 18
All Sexes
Phase 2
Recruiting
Edmonton, Canada
< 18
All Sexes
This study is evaluating whether a combination of pain medicines is more effective than ibuprofen alone for pain management in children with acute MSK injuries.
2
Effectiveness
3
Safety
Apremilast (CC-10004)
for Psoriasis
Edmonton, Canada
< 18
All Sexes
Phase 3
Waitlist Available
Edmonton, Canada
< 18
All Sexes
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis. At least 230 pediatric subjects (ages 6 through 17 years) will be randomized 2:1 to receive either apremilast or placebo for the first 16 weeks and then all subjects will receive apremilast during the 36 week Extension Phase for a total of 52 weeks. Randomization to apremilast arm or placebo arm will be stratified by age group (6 to 11 years or 12 to 17 years). Subjects will receive apremilast treatment of either 20 mg twice daily (BID) or 30 mg BID, depending on weight. This Phase 3 study is being conducted to evaluate the safety and efficacy of apremilast in the treatment of pediatric subjects.
2
Effectiveness
3
Safety
Ozanimod
for Ileocolitis
Tulsa, OK
18+
All Sexes
Phase 3
Recruiting
Tulsa, OK
18+
All Sexes
This study is evaluating whether a drug may help treat Crohn's disease.
2
Effectiveness
3
Safety
Abrocitinib 200 Mg
for Eczema, Infantile
Columbus, GA
Any Age
All Sexes
Phase 3
Waitlist Available
Columbus, GA
Any Age
All Sexes
This study is evaluating whether a drug called Abrocitinib can help treat atopic dermatitis.
1
Effectiveness
1
Safety
Exercises
for Temporomandibular Disorders
Edmonton, Canada
18 - 65
Female
Recruiting
Edmonton, Canada
18 - 65
Female
This study is evaluating whether a therapy that improves neck muscle function can improve pain and brain structure in people with chronic TMD pain.
1
Effectiveness
2
Safety
Pembrolizumab Injection
for Carcinoma
Ottawa, Canada
18+
All Sexes
Phase 2
Recruiting
Metastatic
Ottawa, Canada
18+
All Sexes
Abbreviated Title: Pembrolizumab in Patients with Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) Trial Phase: 2 Clinical Indication: Treatment naïve patients with poor prognosis carcinoma of unknown primary site Trial Type: Single arm phase 2 Type of control: Not applicable Route of administration: Intravenous Trial Blinding: Not applicable Treatment Groups: 1) Pembrolizumab 200 mg IV every 3 weeks for up to 24 months. Total Number of trial subjects:25 Estimated enrollment period: 24 months Estimated duration of trial: 48 months Duration of Participation: 24 months
1
Effectiveness
2
Safety
Dalteparin
for Venous Thromboembolism
Edmonton, Canada
18+
All Sexes
Phase 2
Recruiting
Edmonton, Canada
18+
All Sexes
This study is evaluating whether a weight-adjusted dose of dalteparin is safe for cancer patients that weigh more than 90 kg.
1
Effectiveness
1
Safety
Experimental Intervention
for Antineoplastic Agents
Edmonton, Canada
18+
All Sexes
Waitlist Available
Edmonton, Canada
18+
All Sexes
This study evaluates an eating strategy in adults undergoing chemotherapy for non-small cell lung cancer. Subjects will be allocated to a randomized or observational arm based on baseline measurements. In the randomized arm, half of participants will add certain foods to what they normally eat, while the other half will continue to eat their habitual diet. Subjects in the observational arm will continue to eat their habitual diet.
2
Effectiveness
3
Safety
BIIB093
for Edema
Edmonton, Canada
18+
All Sexes
Phase 3
Recruiting
Edmonton, Canada
18+
All Sexes
The primary objective of Part 1 of the study is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric Infarction (LHI). The secondary objectives of Part 1 of the study are to determine if BIIB093 improves overall survival at Day 90 when compared with placebo, if BIIB093 improves functional outcome at Day 90 on the mRS dichotomized 0-4 vs. 5-6 when compared with placebo, if BIIB093 reduces midline shift at 72 hours (or at time of decompressive craniectomy [DC] or comfort measures only [CMO], if earlier) when compared with placebo, and to evaluate the safety and tolerability of BIIB093 in participants with LHI. The objectives of Part 2 of the study are to evaluate long-term disability following LHI, to evaluate long-term outcome measures of clinical function, quality of life, and healthcare utilization, and to assess the safety of BIIB093 in subjects with LHI during the follow-up period.
1
Effectiveness
1
Safety
GSK3326595
for Lymphoma, Diffuse
Edmonton, Canada
18+
All Sexes
Phase 1
Recruiting
Locally Advanced
Edmonton, Canada
18+
All Sexes
This study is evaluating whether a drug may help treat solid tumors and lymphoma.
2
Effectiveness
3
Safety
Benralizumab
for Eosinophilic Gastritis
Edmonton, Canada
Any Age
All Sexes
Phase 3
Recruiting
Edmonton, Canada
Any Age
All Sexes
This is a 3-part study. Part A and B have identical designs and are randomized, double-blinded, placebo-controlled studies, which will include patients with eosinophilic gastritis and/or duodenal-only disease. Part A will be enrolled first, followed by Part B. After completing Part A or Part B, participants will continue to Part C - open-label benralizumab treatment period.
1
Effectiveness
2
Safety
Tamoxifen
for Relapse
Edmonton, Canada
18+
All Sexes
Phase 2
Recruiting
Edmonton, Canada
18+
All Sexes
This study is evaluating whether tamoxifen is more effective than etoposide for the treatment of recurrent glioblastoma.
2
Effectiveness
3
Safety
CC-93538
for Eosinophilic Esophagitis
Vancouver, WA
Any Age
All Sexes
Phase 3
Recruiting
Vancouver, WA
Any Age
All Sexes
Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants with eosinophilic esophagitis (EoE). The study will incorporate a 24-week Induction Phase followed by a 24-week Maintenance Phase. Participants will be randomized at the beginning of the study into 3 treatment arms: Placebo for Induction and Maintenance CC-93538 360 mg Subcutaneous (SC) once weekly for Induction followed by 360 mg SC once every other week for Maintenance CC-93538 360 mg SC once weekly for Induction and Maintenance
1
Effectiveness
1
Safety
TheraPPP
for Paralysis
Calgary, Canada
18+
All Sexes
Recruiting
Calgary, Canada
18+
All Sexes
This study is evaluating whether a set of activities can improve the quality of care for patients with hypoxemic respiratory failure.
2
Effectiveness
3
Safety
ACE-536
for Myeloproliferative Disorders
Hackensack, NJ
18+
All Sexes
Phase 3
Recruiting
Hackensack, NJ
18+
All Sexes
The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions. The study is divided into Screening Period, a Treatment Phase (consisting of a Blinded Core Treatment Period, a Day 169 Response Assessment, a Blinded Extension Treatment Period, and an Open-label Extension Treatment Period), and a Posttreatment Follow-up Period.
1
Effectiveness
2
Safety
AT-1501
for Diabetes, Autoimmune
Edmonton, Canada
18+
All Sexes
Phase 2
Recruiting
Edmonton, Canada
18+
All Sexes
This study is evaluating whether a new drug can improve the health of people with type 1 diabetes.
1
Effectiveness
1
Safety
Percutaneous Coronary Intervention (PCI)
for Coronary Stenosis
Vancouver, Canada
Any Age
All Sexes
Recruiting
Vancouver, Canada
Any Age
All Sexes
This study is evaluating whether a strategy of complete revascularization involving staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia
2
Effectiveness
3
Safety
Tofacitinib
for Ulcer
New York, NY
< 18
All Sexes
Phase 3
Recruiting
1 Prior Treatment
New York, NY
< 18
All Sexes
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US patients with prior TNFi failure or intolerance will be enrolled. Outside of the US, TNFi naïve and TNFi experienced patients will be enrolled. All eligible participants will initially receive open label tofacitinib at a dose expected to produce equivalent systemic exposure to that observed in adults receiving 5 mg BID with the option for individual dose increase to 10 mg BID adult dose equivalent if dose escalation criteria are met. The primary objective of this study is to evaluate the efficacy of tofacitinib based on remission in pediatric participants with moderately to severely active UC. The primary endpoint is remission by central read Mayo score following 44 weeks in the maintenance phase. Remission is defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. The study Design is an open-label Phase 3 study that includes a screening period of up to 4-weeks duration, an 8-week or 16-week induction phase, a 44-week maintenance phase, and a 24-month extension phase for pediatric participants with moderately to severely active UC. Participants will have a follow-up visit 4 weeks after the last dose of study intervention and a telephone contact 8 weeks later to assess for any adverse events (AEs)/serious adverse events (SAEs). The total maximum duration of this study will be up to 180 weeks.
2
Effectiveness
3
Safety
Encorafenib
for Cancer
Washington, United States
Any Age
All Sexes
Phase 3
Recruiting
Metastatic
Washington, United States
Any Age
All Sexes
This study is evaluating whether a combination of drugs may help treat colorectal cancer.
2
Effectiveness
3
Safety
CPI-0610
for Primary Myelofibrosis
Louisville, KY
18+
All Sexes
Phase 3
Recruiting
Louisville, KY
18+
All Sexes
This study is evaluating whether a drug which blocks a protein in the body may help treat myelofibrosis.
2
Effectiveness
3
Safety
Fenebrutinib
for Multiple Sclerosis
Edmonton, Canada
18 - 65
All Sexes
Phase 3
Recruiting
1 Prior Treatment
Edmonton, Canada
18 - 65
All Sexes
This study is evaluating whether a drug called fenebrutinib may help reduce disability in individuals with a rare disease called RMS.
1
Effectiveness
1
Safety
BT8009
for Cancer
Nashville, TN
18+
All Sexes
Phase 1 & 2
Recruiting
Locally Advanced
Nashville, TN
18+
All Sexes
This clinical trial is evaluating a drug called BT8009 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The main goals of this study are to: Find the recommended dose of BT8009 that can be given safely to participants alone and in combination with nivolumab Learn more about the side effects and effectiveness of BT8009 alone and in combination with nivolumab Learn more about BT8009 alone and in combination with nivolumab Learn more about BT8009 alone in patients with kidney disease
1
Effectiveness
2
Safety
Etrasimod
for Alopecia Areata
Rockville, MD
18+
All Sexes
Phase 2
Recruiting
Rockville, MD
18+
All Sexes
This study is evaluating whether a drug may help treat alopecia areata.
1
Effectiveness
1
Safety
MR Scan With The Alberta Linac-MR P3 System
for Malignancies
Edmonton, Canada
18+
All Sexes
Recruiting
Edmonton, Canada
18+
All Sexes
This study is evaluating whether a new type of radiotherapy machine can safely acquire high quality MR images.
1
Effectiveness
1
Safety
Paclitaxel
for Breast Cancer
Edmonton, Canada
18+
All Sexes
Phase 1
Waitlist Available
Locally Advanced
Edmonton, Canada
18+
All Sexes
This study is evaluating whether a drug called tomivosertib can be safely combined with paclitaxel to treat breast cancer.
2
Effectiveness
3
Safety
Benralizumab
for Airflow Obstruction, Chronic
Columbus, OH
18+
All Sexes
Phase 3
Recruiting
Columbus, OH
18+
All Sexes
Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL). Eligible patients must have a history of ≥2 moderate and/or severe COPD exacerbations in the previous year despite receiving triple (ICS/LABA/LAMA) background therapy for at least 3 months and ICS-based dual inhaled treatment for the remainder of the year. Eligible patients must also have an elevated blood eosinophil count. The treatment period will be of variable duration and will continue until the last patient has the opportunity to complete a minimum of 56 weeks, at which point all patients will complete the study. The primary endpoint will be analyzed at Week 56.
2
Effectiveness
3
Safety
Nivolumab
for Microsatellite Instability
Toronto, Canada
18+
All Sexes
Phase 3
Recruiting
Metastatic
Toronto, Canada
18+
All Sexes
This study is evaluating whether a combination of two immunotherapy drugs may help treat colorectal cancer.
1
Effectiveness
2
Safety
Osimertinib
for Carcinoma
Los Angeles, CA
18+
All Sexes
Phase 2
Waitlist Available
Locally Advanced
Los Angeles, CA
18+
All Sexes
This study is evaluating whether a combination of two drugs may help treat lung cancer.
1
Effectiveness
2
Safety
Avelumab And Radical Radiotherapy
for Carcinoma, Squamous Cell
Edmonton, Canada
18+
All Sexes
Phase 2
Recruiting
Stage I
Edmonton, Canada
18+
All Sexes
This study is evaluating the effectiveness of radiation therapy and Avelumab in treating squamous cell carcinoma of the skin.
1
Effectiveness
2
Safety
Cisplatin
for Carcinoma, Hepatocellular
East Lansing, MI
< 65
All Sexes
Phase 2 & 3
Recruiting
High Risk
East Lansing, MI
< 65
All Sexes
This study is evaluating whether cisplatin and combination chemotherapy may help treat children and young adults with hepatoblastoma or hepatocellular carcinoma.
1
Effectiveness
1
Safety
BMS-986253
for Melanoma
Norfolk, VA
18+
All Sexes
Phase 1 & 2
Recruiting
Locally Advanced
Norfolk, VA
18+
All Sexes
This study is evaluating whether a medication may help treat advanced cancers.
1
Effectiveness
1
Safety
BMS-986249
for Cancer, Advanced
Tyler, TX
18+
All Sexes
Phase 1 & 2
Recruiting
Locally Advanced
Tyler, TX
18+
All Sexes
This study is evaluating whether a drug may help treat solid tumors.
1
Effectiveness
2
Safety
Palbociclib
for Multiple Myeloma
Edmonton, Canada
18+
All Sexes
Phase 2
Recruiting
Metastatic
Edmonton, Canada
18+
All Sexes
This study is evaluating whether a targeted therapy drug can improve the quality of life for people with cancer.
1
Effectiveness
2
Safety
Lyophilized Fecal Microbiota (LFMT)
for Ulcerative Colitis
Edmonton, Canada
18+
All Sexes
Phase 2
Recruiting
Edmonton, Canada
18+
All Sexes
To compare the safety and efficacy of concomitant LFMT versus placebo in UC patients who are starting vedolizumab or ustekinumab.
1
Effectiveness
1
Safety
High Repetition (HI)
for Type 1 Diabetes Mellitus
Edmonton, Canada
18+
Female
Recruiting
Edmonton, Canada
18+
Female
Regular physical activity has substantial health benefits in people with type 1 diabetes. The fear of hypoglycemia, both during and after exercise, is a major barrier to exercise in this population. A major obstacle to providing specific physical activity and exercise advice is that there are still significant gaps in the fundamental understanding of the impact of physical activity and exercise on blood glucose levels in type 1 diabetes. Women with type 1 diabetes have a substantial increase in cardiovascular risk once they have passed menopause. They may lose both bone quality and muscle mass at a faster rate with aging than those without diabetes. Overall, these changes greatly increase the risk of both cardiovascular and frailty related complications. Despite the many potential benefits of resistance exercise for post-menopausal women with type 1 diabetes, there are currently no published studies examining the effects of resistance exercise in this population. Before being able to design a clinical trial of resistance exercise, an examination of the acute effects of resistance exercise on blood glucose levels in post-menopausal women with type 1 diabetes is required. The present study will compare the glycemic effects of a low resistance, high repetition (3 sets of 15 to 20 repetitions) weight lifting program to the effects of a moderate resistance, moderate repetition (3 sets of 8 to 10 repetitions). The investigators hypothesize that the high repetition program will be associated with a bigger decline in blood glucose during exercise, but that the moderate resistance program will be associated with a higher risk of post-exercise hypoglycemia.
1
Effectiveness
1
Safety
Text4Support
for Psychiatric Illness
Edmonton, Canada
18+
All Sexes
Recruiting
1 Prior Treatment
Edmonton, Canada
18+
All Sexes
Avoidable hospital readmissions are a pressing problem for our healthcare system. They lead to substantial human suffering and higher financial costs. Most discharged psychiatric inpatients in Alberta are offered follow-up appointments with Alberta Health Services (AHS) Addiction and Mental Health (AMH) community providers. Patients often wait 28-38 weeks for their first appointment, which leads many to miss their first appointments, and increases the likelihood of relapse. As a result, patients discharged into the community are readmitted to the Emergency Department (ED). To address this significant revolving door, the investigators will implement a low-cost, evidence-based system that delivers daily supportive texts to patients' mobile phones. The text messages developed by experts and service users, based on cognitive behavioral therapy principles. Our proposed program also includes peer support from previous mental health patients who have had similar challenges as participants, but are now in recovery. In this way, the investigators aim to reduce the psychological treatment and support gap for AMH patients who have been discharged from acute care and are scheduled to receive mental health and psychiatric treatment from A&MH services after a long wait. Our pilot test of these interventions provide evidence that psychiatric readmissions, and emergency department visits can be reduced by 10-25% if implemented at scale in Alberta, thus resulting in cost-savings for individuals and the province.
1
Effectiveness
1
Safety
Advanced Cancer Support In Virtual Rehabilitation And Exercise
for Cancer, Advanced
Edmonton, Canada
18+
All Sexes
Recruiting
Locally Advanced
Edmonton, Canada
18+
All Sexes
Background: People with advanced cancer experience fatigue and loss of functioning, which often worsens as their cancer progresses. Rehabilitation programs may help to reduce fatigue and improve overall physical function. People with advanced cancer who live in rural and remote areas lack access to cancer-specific rehabilitation and exercise expertise to manage complex symptoms of high intensity. Their access to in-person services at tertiary sites are further reduced due to public health requirements for physical distancing during the severe acute respiratory syndrome coronavirus 2 pandemic. Aim: To test the feasibility of a virtual program delivered by a team of cancer-specific rehabilitation, exercise and pain and symptom experts for remote and rural patients with advanced cancer to address their symptoms, functioning and quality of life. Design: The virtual program will be tailored to the individual person, and consist of online exercise modules, online supervised interactive group class and one-to-one virtual meetings with an exercise or rehabilitation specialist and a palliative care physician. Relevance: This study will determine whether a virtual multidisciplinary rehabilitation and exercise program is feasible for people with advanced cancer. Further, it will provide insight on how fatigue and loss of functioning can best be managed for this population in remote and rural locations.
1
Effectiveness
2
Safety
NDI-034858 Study Drug
for Psoriasis
Ann Arbor, MI
18+
All Sexes
Phase 2
Waitlist Available
Ann Arbor, MI
18+
All Sexes
This study is evaluating whether a drug called NDI-034858 can help treat psoriasis.
2
Effectiveness
3
Safety
Crinecerfont
for Adrenal Hyperplasia, Congenital
Pittsburgh, PA
< 18
All Sexes
Phase 3
Recruiting
Pittsburgh, PA
< 18
All Sexes
This study is evaluating whether a drug may help treat a rare condition in children.
1
Effectiveness
1
Safety
Synbiotic
for Ileocolitis
Edmonton, Canada
18+
All Sexes
Recruiting
1 Prior Treatment
Edmonton, Canada
18+
All Sexes
This study is evaluating whether a probiotic and fiber supplement can prevent disease recurrence in people with Crohn's disease.
1
Effectiveness
1
Safety
Community Health Navigator Program
for Chronic Kidney Diseases
Edmonton, Canada
18+
All Sexes
Recruiting
Stage III
Edmonton, Canada
18+
All Sexes
This study is evaluating whether a patient navigation program can improve care for patients with long-term health conditions.
1
Effectiveness
2
Safety
Isatuximab
for Neoplasms, Plasma Cell
Saskatoon, Canada
18+
All Sexes
Phase 2
Recruiting
Newly Diagnosed
Saskatoon, Canada
18+
All Sexes
This is a phase II multi-center, open label, single arm study to evaluate the safety and efficacy of Isatuximab administered intravenously in combination with CyBorD induction treatment and Lenalidomide maintenance treatment in a 28-day long cycle in autologous stem cell transplant-eligible patients.
3
Effectiveness
3
Safety
Mavenclad®
for Multiple Sclerosis
London, Canada
18+
All Sexes
Phase 4
Recruiting
1 Prior Treatment
London, Canada
18+
All Sexes
This study is evaluating whether a drug called Mavenclad can help people with multiple sclerosis.
1
Effectiveness
2
Safety
18F-PSMA-1007
for Prostate Cancer
Edmonton, Canada
18+
Male
Phase 2
Recruiting
Metastatic
Edmonton, Canada
18+
Male
Single centre prospective cohort phase II study of 18F-PSMA-1007 PET/CT imaging in patients with biochemically recurrent or high-risk prostate cancer. Safety, biodistribution, clinical efficacy, and diagnostic accuracy will be assessed. For diagnostic accuracy comparison will be made to a contemporary (within 10 days) conventional imaging study (bone scan and CT scan).
2
Effectiveness
3
Safety
AZD9833
for Breast Cancer
Portland, OR
18+
All Sexes
Phase 3
Recruiting
Locally Advanced
Portland, OR
18+
All Sexes
This study is evaluating whether a drug combination may help treat breast cancer.
2
Effectiveness
3
Safety
Tisotumab Vedotin
for Uterine Cervical Neoplasms
Toronto, Canada
18+
Female
Phase 3
Recruiting
Metastatic
Toronto, Canada
18+
Female
This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent). Participants in this trial will be randomly assigned to one of two groups. One group will be treated with tisotumab vedotin. Participants in the other group will get one of five different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, pemetrexed, or irinotecan). Participants and their doctors will know which group they are in. Participants in the chemotherapy group will decide with their study doctor which drug they will take.
2
Effectiveness
3
Safety
Mirikizumab
for Ileocolitis
Richmond, VA
18+
All Sexes
Phase 3
Recruiting
Richmond, VA
18+
All Sexes
This study is evaluating whether a drug may help treat Crohn's disease.
2
Effectiveness
3
Safety
Dupilumab SAR231893
for Urticaria
Dallas, TX
Any Age
All Sexes
Phase 3
Waitlist Available
Dallas, TX
Any Age
All Sexes
Primary Objective: To demonstrate the efficacy of dupilumab in study participants with CSU who remain symptomatic despite the use of H1 antihistamine (Study A and C: omalizumab naïve; Study B: omalizumab intolerant or incomplete responders) Secondary Objectives: To demonstrate the efficacy of dupilumab on urticaria activity composite endpoint and itch or hives, separately, at various timepoints To demonstrate the efficacy of dupilumab on angioedema To demonstrate the efficacy of dupilumab on urticaria control To demonstrate improvement in health-related quality of life and overall disease status and severity To evaluate the ability of dupilumab in reducing the proportion of patients who require treatment with oral corticosteroids (OCS) To evaluate safety outcome measures To evaluate immunogenicity of dupilumab
1
Effectiveness
1
Safety
Autologous CD19-directed Chimeric Antigen Receptor (CAR) T-cells
for Leukemia, Lymphoid
Edmonton, Canada
Any Age
All Sexes
Phase 1 & 2
Recruiting
1 Prior Treatment
Edmonton, Canada
Any Age
All Sexes
This study is evaluating whether a new type of immune cell can be created to fight cancer.
3
Effectiveness
3
Safety
Evolocumab
for Atherogenesis
Jacksonville, FL
18+
All Sexes
Phase 4
Recruiting
Jacksonville, FL
18+
All Sexes
This study is evaluating whether a medication may help improve blood flow in veins that have been used for bypass surgery.
1
Effectiveness
2
Safety
Odronextamab
for Lymphoma, Diffuse
Dallas, TX
18+
All Sexes
Phase 2
Recruiting
Grade I
Dallas, TX
18+
All Sexes
This study is evaluating whether a drug called odronextamab can help treat people with lymphoma.
1
Effectiveness
1
Safety
Break Wave Extracorporeal Lithotripsy
for Calculi
Edmonton, Canada
18+
All Sexes
Recruiting
Edmonton, Canada
18+
All Sexes
This is a prospective, open-label, multi-center, single-arm (non-randomized) study to assess the safety and effectiveness of breaking stones in the upper urinary tract using the SonoMotion Break Wave technology. Up to 30 subjects will be included. The procedure will be performed in a hospital surgical environment as an outpatient (without being admitted) or in a non-surgical environment such as a clinic or office procedure room. The procedure will be performed under varying levels of anesthesia ranging from no anesthesia to general anesthesia (fully asleep). Stones will be limited to ≤ 10 mm for lower pole stones and ≤ 20 mm everywhere else. Safety will be measured by the self-reported occurrences of adverse events, unplanned emergency department or clinic visits, and the need for further intervention. Fragmentation will be measured by self-reported stone passage and a comparison of computed tomography (CT) images before and after the procedure.
2
Effectiveness
3
Safety
Cholecalciferol
for Vitamin D Deficiency
Edmonton, Canada
< 18
All Sexes
Phase 3
Recruiting
Edmonton, Canada
< 18
All Sexes
This study is evaluating whether a single dose of vitamin D can improve survival and health-related quality of life in critically ill children.
1
Effectiveness
1
Safety
Intensive Exercise
for Cerebral Palsy
Edmonton, Canada
< 18
All Sexes
Recruiting
Edmonton, Canada
< 18
All Sexes
This study is evaluating whether intensive leg exercise is more effective than standard physiotherapy care for improving gross motor function in young children with spastic diplegia.
2
Effectiveness
3
Safety
Hippocampal-avoidant (HA-WBRT) Radiotherapy
for Neoplasm Metastasis
Saint Louis, MO
18+
All Sexes
Phase 3
Recruiting
Metastatic
Saint Louis, MO
18+